Pentosan polysulfate treatment ameliorates motor function with increased serum soluble vascular cell adhesion molecule-1 in HTLV-1-associated neurologic disease

详细信息    查看全文

• 作者：Tatsufumi Nakamura (1)
  Katsuya Satoh (1)
  Taku Fukuda (2)
  Ikuo Kinoshita (3)
  Yoshihiro Nishiura (4)
  Kunihiko Nagasato (4)
  Atsushi Yamauchi (5)
  Yasufumi Kataoka (5)
  Tadahiro Nakamura (6)
  Hitoshi Sasaki (6)
  Kenji Kumagai (7)
  Masami Niwa (8)
  Mitsuru Noguchi (9)
  Hideki Nakamura (2)
  Noriyuki Nishida (1)
  Atsushi Kawakami (2)
  
• 关键词：HTLV ; I ; HAM/TSP ; Pentosan polysulfate ; Soluble adhesion molecule
• 刊名：Journal of NeuroVirology
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：20
• 期：3
• 页码：269-277
• 全文大小：
• 参考文献：1. Ando H, Sato T, Tomaru U, Yoshida M, Utsunomiya A, Yamauchi J, Araya N, Yagishita N, Coler-Reilly A, Shimizu Y, Yudoh K, Hasegawa Y, Nishioka K, Nakajima T, Jacobson S, Yamano Y (2013) Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy. Brain 136:2876-887 CrossRef
  2. Araya N, Takahashi K, Sato T, Nakamura T, Sawa C, Hasegawa D, Ando H, Aratani S, Yagishita N, Fujii R, Oka H, Nishioka K, Nakajima T, Mori N, Yamano Y (2011) Fucoidan therapy decreases the proviral load in patients with human T-lymphotropic virus type-1-associated neurological disease. Antivir Ther 16:89-8 CrossRef
  3. Aye MM, Matsuoka E, Moritoyo T, Umehara F, Suehara M, Hokezu Y, Yamanaka H, Isashiki Y, Osame M, Izumo S (2000) Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol 100:245-52 CrossRef
  4. Best I, Adaui V, Verdonck K, González E, Tipismana M, Clark D, Gotuzzo E, Vanham G (2006) Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 146:226-33 CrossRef
  5. Bohannon RW, Smith MB (1987) Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-07
  6. Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF (1997) Increases in soluble VCAM- I correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-I b. Ann Neurol 41:669-74 CrossRef
  7. de-Thé G, Bomford R (1993) An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 9:381-86 CrossRef
  8. Fukushima N, Nakamura T, Nishiura Y, Ida H, Aramaki T, Eguchi K (2008) HTLV-I production based on activation of integrin/ligand signaling in HTLV-I-infected T cell lines derived from HAM/TSP patients. Intervirology 51:1234-239 CrossRef
  9. Ghosh P (1999) The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheum 28:211-67 CrossRef
  10. Guerreiro JB, Santos SB, Morgan DJ, Porto AF, Muniz AL, Ho JL, Teixeira AL Jr, Teixeira MM, Carvalho EM (2006) Levels of serum chemokines discriminate clinical myelopathy associated with human T lymphotropic virus type 1 (HTLV-1)/tropical spastic paraparesis (HAM/TSP) disease from HTLV-1 carrier state. Clin Exp Immunol 145:296-01 CrossRef
  11. Hollsberg P, Hafler DA (1993) Pathogenesis of diseases induced by human T-lymphotropic virus type I infection. N Engl J Med 328:1173-182 CrossRef
  12. Ida H, Kurata A, Eguchi K, Yamashita I, Nakashima M, Sakai M, Kawabe Y, Nakamura T, Nagataki S (1994) Mechanism of inhibitory effect of dextran sulfate and heparin on human T-cell lymphotropic virus type I (HTLV-I)-induced syncytium formation in vitro: role of cell to cell contact. Antiviral Res 23:143-59 CrossRef
  13. Igakura T, Stinchcombe JC, Goon PK, Taylor GP, Weber JN, Griffiths GM, Tanaka Y, Osame M, Bangham CR (2003) Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299:1713-716 CrossRef
  14. Ijichi S, Izumo S, Eiraku N, Machigashira K, Kubota R, Nagai M, Ikegami N, Kashio N, Umehara F, Maruyama I, Osame M (1993) An autoaggressive process against bystander tissues in HTLV-I-infected individuals: a possible pathomechanism of HAM/TSP. Med Hypotheses 41:542-47 CrossRef
  15. Irony-Tur-Sinai M, Vlodavsky I, Ben-Sasson SA, Pinto F, Sicsic C, Brenner T (2003) A synthetic heparin-mimicking polyanionic compound inhibits central nervous system inflammation. J Neurol Sci 206:49-7 CrossRef
  16. Izumo S, Usuku K, Osame M, Machigashira K, Johnosono M, Nakagawa M (1989) The neuropathology of HLV-I-associated myelopathy in Japan: report of an autopsy case and review of the literature. In: Román GC, Vernant J-C, Osame M (eds) HTLV-I and the nervous system. Alan R, Liss, Inc, New York, pp 261-67
  17. Jones KS, Petrow-Sadowski C, Bertolette DC, Huang Y, Ruscetti FW (2005) Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells. J Virol 79:12692-2702 CrossRef
  18. Kallmann BA, Hummel V, Lindenlaub T, Ruprecht K, Toyka KV, Rieckmann P (2000) Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1. Brain 123:687-97 CrossRef
  19. Kumagai K, Shirabe S, Miyata N, Murata M, Yamauchi A, Kataoka Y, Niwa M (2010) Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis—an open clinical trial. BMC Clin Pharma 10:7 CrossRef
  20. Matsuda M, Tsukada N, Miyagi K, Yanagisawa N (1995) Increased levels of soluble vascular cell adhesion molecule-l (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. J Neuroimmunol 59:35-0 CrossRef
  21. Nagasato K, Nakamura T, Ichinose K, Nishiura Y, Ohishi K, Shibayama K, Watanabe H, Tsujihata M, Nagataki S (1993) Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy. J Neurol Sci 115:161-68 CrossRef
  22. Nakamura T, Nishiura Y, Eguchi K (2009) Therapeutic strategies in HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Cent Nerv Syst Agents Med Chem 9:137-49 CrossRef
  23. Nakamura T (2009) HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy. Folia Neuropathol 47:182-94
  24. Nishiura Y, Nakamura T, Fukushima N, Nakamura H, Ida H, Aramaki T, Eguchi K (2009) Disulfide-mediated apoptosis of human T-lymphotropic virus type-I (HTLV-I)-infected cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Antivir Ther 14:533-42
  25. Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, Tara M, Igata A (1987) Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia-like cells. Ann Neurol 21:117-22 CrossRef
  26. Osame M, Igata A, Matsumoto M (1989) HTLV-I-associated myelopathy (HAM) revisited. In: Román GC, Vernant J-C, Osame M (eds) HTLV-I and the nervous system. Alan R, Liss, Inc, New York, pp 213-23
  27. Osame M (1990) Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA (ed) Human retrovirology: HTLV. Raven, New York, pp 191-97
  28. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N (1993) Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. Ann Neurol 33:646-49 CrossRef
  29. Umehara F, Izumo S, Takeya M, Takahashi K, Sato E, Osame M (1996) Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. Acta Neuropathol 91:343-50 CrossRef
  30. Wattel E, Vartanian JP, Pannetier C, Wain-Hobson S (1995) Clonal expansion of human T-cell leukemia virus type I-infected cells in asymptomatic and symptomatic carriers without malignancy. J Virol 69:2863-868
  31. Weiner HL, Hafler DA (1988) Immunotherapy of multiple sclerosis. Ann Neurol 23:211-22 CrossRef
  32. Yoshida A, Piroozmand A, Sakurai A, Fujita M, Uchiyama T, Kimura T, Hayashi Y, Kiso Y, Adachi A (2005) Establishment of a biological assay system for human retroviral protease activity. Microbes Infect 7:820-24 CrossRef
  
• 作者单位：Tatsufumi Nakamura (1)
  Katsuya Satoh (1)
  Taku Fukuda (2)
  Ikuo Kinoshita (3)
  Yoshihiro Nishiura (4)
  Kunihiko Nagasato (4)
  Atsushi Yamauchi (5)
  Yasufumi Kataoka (5)
  Tadahiro Nakamura (6)
  Hitoshi Sasaki (6)
  Kenji Kumagai (7)
  Masami Niwa (8)
  Mitsuru Noguchi (9)
  Hideki Nakamura (2)
  Noriyuki Nishida (1)
  Atsushi Kawakami (2)
  
  1. Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
  2. Translational Medicine Unit, Department of Clinical Neuroscience and Neurology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
  3. Neurology Section, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan
  4. Neurology Section, Isahaya Health Insurance General Hospital, Nagasaki, Japan
  5. Department of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan
  6. Department of Hospital Pharmacy, Nagasaki University Hospital, Nagasaki, Japan
  7. Orthopaedic Surgery Section, Ekisaikai Hospital, Nagasaki, Japan
  8. Department of Pharmacology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
  9. Department of Urology, Saga University Faculty of Medicine, Saga, Japan
  
• ISSN：1538-2443

文摘

The main therapeutic strategy against human T lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) characterized by lower extremity motor dysfunction is immunomodulatory treatment, with drugs such as corticosteroid hormone and interferon-α, at present. However, there are many issues in long-term treatment with these drugs, such as insufficient effects and various side effects. We now urgently need to develop other therapeutic strategies. The heparinoid, pentosan polysulfate sodium (PPS), has been safely used in Europe for the past 50?years as a thrombosis prophylaxis and for the treatment of phlebitis. We conducted a clinical trial to test the effect of subcutaneous administration of PPS in 12 patients with HAM/TSP in an open-labeled design. There was a marked improvement in lower extremity motor function, based on reduced spasticity, such as a reduced time required for walking 10?m and descending a flight of stairs. There were no significant changes in HTLV-I proviral copy numbers in peripheral blood contrary to the inhibitory effect of PPS in vitro for intercellular spread of HTLV-I. However, serum soluble vascular cell adhesion molecule (sVCAM)-1 was significantly increased without significant changes of serum level of chemokines (CXCL10 and CCL2). There was a positive correlation between increased sVCAM-1and reduced time required for walking 10?m. PPS might induce neurological improvement by inhibition of chronic inflammation in the spinal cord, through blocking the adhesion cascade by increasing serum sVCAM-1, in addition to rheological improvement of the microcirculation. PPS has the potential to be a new therapeutic tool for HAM/TSP.